Mifepristone and Mid-Trimester Termination of Pregnancy

This study has been completed.
Sponsor:
Information provided by:
Boston University
ClinicalTrials.gov Identifier:
NCT00382538
First received: September 28, 2006
Last updated: October 3, 2008
Last verified: October 2008
  Purpose

Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. The following day, the woman is admitted and given sequential doses of misoprostol until delivery occurs. The average length of time between the first dose of misoprostol and delivery is 12 hours, requiring most women to stay overnight. This is a randomized, placebo-controlled, double-blinded study designed to determine whether adding mifepristone significantly reduces the induction interval time (time between starting the first misoprostol and delivery) required for a second trimester termination.


Condition Intervention
Abortion, Induced
Abortion, Second Trimester
Drug: Addition of mifepristone 200 mg 24 hours before induction

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy

Resource links provided by NLM:


Further study details as provided by Boston University:

Primary Outcome Measures:
  • Time from start of induction to fetal delivery

Estimated Enrollment: 64
Study Start Date: March 2005
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   16 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 16 years of age or over
  • able to give informed consent in English or Spanish
  • Requesting termination of pregnancy

Exclusion Criteria:

  • Under 16 years of age
  • rupture membranes or intrauterine death
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00382538

Locations
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Boston University
Investigators
Principal Investigator: Lynn Borgatta, MD, MPH Boston University
  More Information

No publications provided by Boston University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00382538     History of Changes
Other Study ID Numbers: 24597
Study First Received: September 28, 2006
Last Updated: October 3, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Boston University:
mifepristone
induction
abortion
injection, intra-amniotic

Additional relevant MeSH terms:
Mifepristone
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Abortifacient Agents, Steroidal
Abortifacient Agents

ClinicalTrials.gov processed this record on April 15, 2014